Neutropenia Management
Definition and Classification
- Neutropenia is defined as an absolute neutrophil count (ANC) below 1500 cells/mm³, with severity classification including mild (ANC 1000-1500 cells/mm³), moderate (ANC 500-1000 cells/mm³), and severe (ANC < 500 cells/mm³), according to the American Society of Clinical Oncology and the National Comprehensive Cancer Network 1, 2, 3, 4
Causes of Neutropenia
- Chemotherapeutic agents are the most common cause of neutropenia in clinical practice, according to the National Comprehensive Cancer Network 5
- Other causes of neutropenia include:
Risk of Infection
- The risk of infection increases with severity and duration of neutropenia, and rate of decline in neutrophil count, with significant risk at an ANC < 500/μL, particularly high at < 100/μL 1, 2, 5, 7, 4
- Primary sites of infection in neutropenic patients include the alimentary tract, sinuses, lungs, and skin, with common pathogens including gram-positive bacteria, gram-negative bacteria, antibiotic-resistant bacteria, fungi, and viruses 2, 8, 9
Diagnostic Approach
- Evaluation of neutropenia should include:
- Travel history is crucial in evaluating neutropenia, with testing for malaria important even in patients who have taken anti-malarial prophylaxis or residents from endemic areas who are thought to be immune 7, 1
Treatment and Management
- Prompt antibiotic therapy is recommended in febrile neutropenia, and appropriate use of granulocyte-colony stimulating factor (G-CSF) to reduce the risk of serious infections and improve outcomes, as recommended by the American College of Physicians and other medical societies 5
- Empiric antibiotics may be necessary if febrile neutropenia develops, and hematopoietic growth factors (G-CSF, pegfilgrastim) may be indicated for primary prophylaxis when the risk of febrile neutropenia exceeds 20% with chemotherapy, and for treatment of established febrile neutropenia in settings with increased morbidity/mortality, as recommended by the Infectious Diseases Society of America and the Annals of Oncology 1, 8, 9
- Treating the underlying parasitic infection is essential for patients with neutropenia potentially related to parasitic infection, and for malaria, rapid blood malaria antigen tests and three thick and thin blood films should be performed 7
- Febrile neutropenia is specifically defined as a temperature >38.5°C for >1 hour with an ANC <500 cells/mm³, and requires prompt evaluation and treatment, with fever often being the only sign of infection in neutropenic patients, as noted by the National Comprehensive Cancer Network and the Annals of Oncology 2, 8, 9
- Growth factors should be avoided in patients with infections not related to neutropenia, such as community or hospital-acquired pneumonia, and G-CSF is contraindicated during radiotherapy to the chest due to increased complications and mortality, and should be avoided immediately before or with chemotherapy due to risk of worsening thrombocytopenia, as warned by the Annals of Oncology 8, 9, 4
- Patients with certain types of chronic neutropenia (particularly congenital forms) may have an increased risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), which may be higher in patients receiving long-term G-CSF therapy, as reported by the Annals of Oncology 9
- Common errors in neutropenia management include delaying antibiotic therapy in febrile neutropenia, failing to recognize drug-induced neutropenia, overlooking underlying causes in chronic neutropenia, and using G-CSF inappropriately, as noted by the Infectious Diseases Society of America 10